Altor BioScience Corporation
2810 North Commerce Parkway
Miramar
Florida
33025-3958
United States
Tel: 954-443-8600
Fax: 954-443-8610
Website: http://www.altorbioscience.com/
Email: rwong@altorbioscience.com
26 articles about Altor BioScience Corporation
-
Billionaire biotech entrepreneur Patrick Soon-Shiong has his eyes set on taking his newly formed oncology-focused Nant public this year.
-
The feud stems from a Florida-based pharmaceutical startup, Altor BioScience, which Cher invested in.
-
Iconic Cher Sues NantHealth's Soon-Shiong Over Altor BioScience Stock Fraud
10/3/2017
-
Despite 'Lowball' Offer, NantCell's Soon-Shiong Snags Altor BioScience In $290 Million Deal
6/27/2017
-
NantHealth's Soon-Shiong Sued for Attempting to Take Over Altor BioScience for a Lowball Price
6/22/2017
-
Altor BioScience Corporation Announces FDA Fast Track Designation For Lead Candidate ALT-803 In Patients With Non-Muscle Invasive Bladder Cancer
5/2/2017
-
Altor BioScience Corporation And CMC Biologics Announce Agreement For Manufacture And Validation Of Altor's IL-15 Superagonist Molecule, ALT-803, For Use In Phase III Clinical Trials
4/14/2017
-
Altor BioScience Corporation And NantKwest Announce Co-Development Agreement To Advance Innovative Natural Killer Cell Combination Immunotherapies For The Treatment Of Cancer
10/4/2016
-
Altor BioScience Corporation Partners With The NCI To Further Develop Altor’s ALT-803 And ALT-801 Cancer Immunotherapeutics
4/11/2016
-
Altor BioScience Corporation Announces The Appointment Of Dr. Patrick Soon-Shiong As Chairman Of Its Board Of Directors
4/7/2016
-
Altor BioScience Corporation Announces National Cancer Institute Phase II SBIR Grant Award And Publication Supporting Ongoing Clinical Trial Of IL-15 Super Agonist ALT-803 In Combination With Anti-CD20 Antibody Therapy For Relapsed / Refractory Non-Hodgki
10/6/2015
-
ASCO15: Altor BioScience Corporation Announces Upcoming Data Presentation On Efficacy And Safety Of ALT-801 For Advanced Bladder Cancer At 2015 ASCO Annual Meeting
5/28/2015
-
Altor BioScience Corporation Announces The Appointment Of Kevin Taylor As Chief Business Officer
1/6/2015
-
Altor BioScience Corporation Initiates Clinical Development Of Its Novel IL-15 Super Agonist ALT-803 For Relapsed / Refractory Multiple Myeloma Supported By A Newly Awarded Phase 2 SBIR Grant From National Cancer Institute
11/4/2014
-
Shenzhen Beike Biotechnology Co. Ltd., Altor BioScience Corporation Strike $200 Million Cancer Deal
9/10/2014
-
Altor BioScience Corporation Awarded SBIR Phase 2 Grant By NCI For Clinical Development Of Its Novel IL-15 Super Agonist For Non-Muscle Invasive Bladder Cancer
8/19/2014
-
Altor BioScience Corporation Launches Its Proprietary IL-15 Superagonist ALT-803 Into Clinical Trials Against Cancer
8/15/2013
-
Altor BioScience Corporation and the Melanoma Research Alliance to Co-Support Clinical Studies of Altor’s Novel IL-15 Superagonist for Metastatic Melanoma
4/30/2012
-
Florida Biologix(R) Announces Manufacturing Agreement with Altor BioScience Corporation
6/28/2011
-
Altor BioScience Corporation Awarded $3 MM SBIR Phase II Competing Renewal Grant by NHBLI
5/23/2011